BIRMINGHAM, Ala., May 12 /PRNewswire/ -- Lakeshore Biomaterials today named two new executives to its staff. Joining Lakeshore are Paul Spencer and John Middleton. Lakeshore Biomaterials ( http://www.lakeshorebiomaterials.com/ ) is a wholly-owned subsidiary of Brookwood Pharmaceuticals, which was recently spun- out from Southern Research Institute. Lakeshore supplies biodegradable polymers to the pharmaceutical industry.
“I am very excited to have such outstanding individuals join our team,” says Arthur J. Tipton, Ph.D., Brookwood Pharmaceuticals president and CEO. “The addition of these two highly-accomplished professionals adds depth to our organization, and the skills they bring will help Brookwood and Lakeshore achieve their goals, ideals and strategic objectives.”
Paul Spencer was named vice president and general manager of Lakeshore Biomaterials. Spencer brings more than 20 years of leadership experience including more than 14 years in the pharmaceutical, drug delivery, and medical device industries. Prior to joining Lakeshore Biomaterials, he worked at Alkermes in the Business Development group where he was primarily responsible for worldwide sales and marketing, business strategy, product development and customer service for the Medisorb(R) bioabsorbable polymer business unit. He also worked on injectable drug delivery projects while at Alkermes. Spencer’s prior experience includes being a top sales consultant and distributor at Biomet’s Subsidiary, W’Lorenz Surgical, where he was involved in the launch and commercialization of the world’s first craniomaxillofacial absorbable plating system. He also served more than six years as an aviation officer in the United States Army in numerous command positions in the U.S. and internationally. Spencer holds a bachelor’s degree in Quantitative Business Analysis from Indiana University.
John Middleton was named chief scientific officer of Lakeshore Biomaterials. He has been synthesizing biodegradable polymers since the early 1980s. As the vice president and technical director of Birmingham Polymers, Inc. (BPI), he directed the day-to-day operations of the company from 1996- 2001. During that time he was involved in the synthesis of over 600 batches of polymer and commercialized five products. Dr. Middleton has published 18 articles in scientific and trade journals and holds two patents. He received his doctorate in Polymer Science from the University of Southern Mississippi.
About Brookwood Pharmaceuticals, Inc.
Brookwood Pharmaceuticals is based in Birmingham, Alabama, with formulation and scale up laboratories, clean rooms and a quality system that supports the manufacture of materials for clinical trials and market introduction. The company formulates long-acting products for its clients’ active pharmaceutical ingredients (API). Key target APIs includes peptides, proteins, nucleic acids, small molecules, generics and low-dose molecules. Brookwood Pharmaceuticals holds more than 20 patents and is adding new patents and technology to its portfolio. For more information, visit http://www.brookwoodpharma.com/ .
Media Contact: Thomas R. Tice, Ph.D., Brookwood Pharmaceuticals, Inc.
205-917-2220, tice@brookwoodpharma.com
Southern Research Institute
CONTACT: Thomas R. Tice, Ph.D. of Brookwood Pharmaceuticals, Inc.,+1-205-917-2220, or tice@brookwoodpharma.com
